In order to assess whether the effects of PPARG inhibition are specific to AML, we compared the effect of a 48‐h treatment with GW9662 on the growth of AML cells (UMB, SV7, and T4‐Xn) to its effect on the cervical cancer cell line HeLa and primary cells derived from the renal neoplasm Wilms' tumor (WT). Here, PPARG is linked to acute myeloid leukemia.